Biomarkers of drug-induced liver injury.
Biomarkers of drug-induced liver injury.
复制标题
DOI：
10.1016/bs.apha.2019.02.001
复制
发表时间：
2019-01-01
期刊：
影响因子：
--
通讯作者：
Jaeschke, Hartmut
中科院分区：
文献类型：
--
作者：
McGill, Mitchell R;Jaeschke, Hartmut
药物性肝损伤（DILI）是一个主要的临床和监管挑战。因此，对DILI生物标志物的兴趣正在增长。到目前为止，在用于诊断（对乙酰氨基酚-半胱氨酸蛋白加合物）、预测（遗传生物标志物）和预后（microRNA-122、高迁移率族蛋白1、角蛋白-18、谷氨酸脱氢酶、线粒体DNA）的生物标志物的鉴定方面已经取得了相当大的进展。这些生物标志物中的许多也提供了机制见解。本章的目的是回顾过去十年DILI生物标志物研究的主要进展，并强调实施中涉及的一些挑战。尽管已经做了很多工作，但仍然需要更多的肝脏特异性生物标志物，更多的DILI特异性生物标志物和更好的预后生存生物标志物。此外，还需要做更多的工作来定义参考区间和医疗决策界限。
Drug-induced liver injury (DILI) is a major clinical and regulatory challenge. As a result, interest in DILI biomarkers is growing. So far, considerable progress has been made in identification of biomarkers for diagnosis (acetaminophen-cysteine protein adducts), prediction (genetic biomarkers), and prognosis (microRNA-122, high mobility group box 1 protein, keratin-18, glutamate dehydrogenase, mitochondrial DNA). Many of those biomarkers also provide mechanistic insight. The purpose of this chapter is to review major advances in DILI biomarker research over the last decade, and to highlight some of the challenges involved in implementation. Although much work has been done, more liver-specific biomarkers, more DILI-specific biomarkers, and better prognostic biomarkers for survival are all still needed. Furthermore, more work is needed to define reference intervals and medical decision limits.